دورية أكاديمية
Validation of a novel ELISA for measurement of MDA-LDL in human plasma.
| العنوان: | Validation of a novel ELISA for measurement of MDA-LDL in human plasma. |
|---|---|
| المؤلفون: | Bevan RJ; Department of Clinical Biochemistry, University of Leicester, Leicester, UK, Durand MF, Hickenbotham PT, Kitas GD, Patel PR, Podmore ID, Griffiths HR, Waller HL, Lunec J |
| المصدر: | Free radical biology & medicine [Free Radic Biol Med] 2003 Sep 01; Vol. 35 (5), pp. 517-27. |
| نوع المنشور: | Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: United States NLM ID: 8709159 Publication Model: Print Cited Medium: Print ISSN: 0891-5849 (Print) Linking ISSN: 08915849 NLM ISO Abbreviation: Free Radic Biol Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Tarrytown, NY : Elsevier Science Original Publication: New York : Pergamon, c1987- |
| مواضيع طبية MeSH: | Enzyme-Linked Immunosorbent Assay/*methods , Lipoproteins, LDL/*blood , Malondialdehyde/*blood , Myocardial Ischemia/*blood, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Animals ; Apolipoproteins B/blood ; Apolipoproteins B/immunology ; Case-Control Studies ; Copper/pharmacology ; F2-Isoprostanes/metabolism ; Female ; Gas Chromatography-Mass Spectrometry ; Humans ; Immunoglobulins/immunology ; Lipid Peroxidation/physiology ; Male ; Mice ; Mice, Inbred BALB C ; Middle Aged ; Myocardial Ischemia/pathology ; Oxidation-Reduction ; Rabbits ; Risk Factors ; Thiobarbiturates/metabolism |
| مستخلص: | The involvement of oxidatively modified low density lipoprotein (LDL) in the development of CHD is widely described. We have produced two antibodies, recognizing the lipid oxidation product malondialdehyde (MDA) on whole LDL or ApoB-100. The antibodies were utilized in the development of an ELISA for quantitation of MDA-LDL in human plasma. Intra- and inter-assay coefficients of variation (% CV) were measured as 4.8 and 7.7%, respectively, and sensitivity of the assay as 0.04 micro g/ml MDA-LDL. Recovery of standard MDA-LDL from native LDL was 102%, indicating the ELISA to be specific with no interference from other biomolecules. Further validation of the ELISA was carried out against two established methods for measurement of lipid peroxidation products, MDA by HPLC and F(2)-isoprostanes by GC-MS. Results indicated that MDA-LDL is formed at a later stage of oxidation than either MDA or F(2)-isoprostanes. In vivo analysis demonstrated that the ELISA was able to determine steady-state concentrations of plasma MDA-LDL (an end marker of lipid peroxidation). A reference range of 34.3 +/- 8.8 micro g/ml MDA-LDL was established for healthy individuals. Further, the ELISA was used to show significantly increased plasma MDA-LDL levels in subjects with confirmed ischemic heart disease, and could therefore possibly be of benefit as a diagnostic tool for assessing CHD risk. |
| المشرفين على المادة: | 0 (Apolipoproteins B) 0 (F2-Isoprostanes) 0 (Immunoglobulins) 0 (Lipoproteins, LDL) 0 (Thiobarbiturates) 4Y8F71G49Q (Malondialdehyde) 789U1901C5 (Copper) M1YZW5SS7C (thiobarbituric acid) |
| تواريخ الأحداث: | Date Created: 20030821 Date Completed: 20040401 Latest Revision: 20191210 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/s0891-5849(03)00359-9 |
| PMID: | 12927601 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0891-5849 |
|---|---|
| DOI: | 10.1016/s0891-5849(03)00359-9 |